Figure 2
Figure 2. Procr+/− genotype mildly enhances hemostatic parameters after factor Xa/PCPSPE challenge and has synergetic effects with TM antibody. The mice were challenged with factor Xa/PCPSPE, and the parameters were measured in the samples collected 10 minutes after challenge. (A) Levels of TAT complex in the plasma of Procr +/+ mice (n = 14), Procr +/− mice (n = 14), Procr +/+ mice with TM antibody (n = 5), and Procr +/− mice with TM antibody (n = 5). (B) Levels of circulating fibrinogen level. The fibrinogen levels are relative to the level of resting Procr +/+ mice (100%). (C) Platelet counts in the blood. (D) APC/TAT ratios in the plasma. (E) APC levels in the plasma. #P < .01, *P < .05, compared with Procr +/+ mice. Results are presented as mean ± SD.

Procr+/− genotype mildly enhances hemostatic parameters after factor Xa/PCPSPE challenge and has synergetic effects with TM antibody. The mice were challenged with factor Xa/PCPSPE, and the parameters were measured in the samples collected 10 minutes after challenge. (A) Levels of TAT complex in the plasma of Procr+/+ mice (n = 14), Procr+/− mice (n = 14), Procr +/+ mice with TM antibody (n = 5), and Procr +/− mice with TM antibody (n = 5). (B) Levels of circulating fibrinogen level. The fibrinogen levels are relative to the level of resting Procr+/+ mice (100%). (C) Platelet counts in the blood. (D) APC/TAT ratios in the plasma. (E) APC levels in the plasma. #P < .01, *P < .05, compared with Procr+/+ mice. Results are presented as mean ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal